New hub’s mission is to provide the world with better data, analytics and decisions to detect and respond to health emergencies

Each tumor consists of multiple cell types, all of which have distinct characteristics. In addition to determining the course of the disease, these differences between individual cancer cells control the effectiveness of targeted therapies. A team of…

-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment-

-Received $20 million upfront payment from Otsuka as part of the first major collaboration between a…

A clinical trial, conducted by an international team of researchers and co-led by Charité – Universitätsmedizin Berlin, has shown that a triple combination therapy consisting of three known compounds is both safe and effective in cystic fibrosis…

ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to develop their lead vaccine. The signing of the agreement is yet another milestone in a series of fruitful…

Björn von Siemens is co-founder and managing director of caresyntax GmbH. The company develops algorithms that analyze risk factors during surgery and provide decision support. The company, based in Berlin and Boston, recently raised 100 million US…

– Seventure Partners and Novartis Pharmaceuticals join as new investors

– Transformative treatment for millions of children with myopia

Berlin, Germany, July 14, 2021 — Dopavision, a company pioneering the development of digital therapeutics,…

Berlin, Germany and Duarte, USA, June 9, 2021:

ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening…